Mandate

Vinge advises Biotage in connection with its acquisition of PhyNexus

December 06, 2018 Capital Markets and Public M&A

Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.


The transaction is expected to be completed in January 2019 and is subject to customary closing conditions.

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017.

Vinge’s team consists of Dain Hård Nevonen, Malte Hedlund and Josephine Andersson. 

Related

Vinge advises EQT in connection with the sale of Eton

Vinge has advised EQT VII in connection with its sale of Eton to a consortium of private investors.
July 01, 2025

Vinge advises Triton in connection with the acquisition of Prenax

Vinge has advised Triton Smaller Mid Cap Fund II in connection with the acquisition of Prenax from LBO France and certain minority shareholders.
July 01, 2025

Vinge advises Impilo on the establishment of Impilo Healthcare

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.
July 01, 2025